High Symptom Burden of NonAdvSM Diminishes Daily Functioning and Well-Being Adults with nonAdvSM in the Summit study reported a high symptom burden that affects daily functioning and emotional well-being.

Adults with nonadvanced systemic mastocytosis (#nonAdvSM) reported a high symptom burden that affects daily functioning and emotional well-being, according to findings from patient entry interviews conducted as part of the Phase 2 #SUMMIT trial of #Bezuclastinib.

Read More: https://bit.ly/4cPNtv4

Bezuclastinib Shows Safety, Symptom Improvement vs Placebo in NonAdvSM Bezuclastinib produced clinically meaningful improvements in SM symptom control and disease biomarkers compared with placebo, according to new research.

Researchers reported the statistically significant superiority of #Bezuclastinib to placebo in patients with nonadvanced #SystemicMastocytosis (#NonAdvSM). Results will be presented at the 67th @ash.hematology.org Annual Meeting and Exposition

Read more: https://bit.ly/4pMy4Pt

#RareDisease #MedSky

What about- Did you know? There is an Expanded Access Program that gives advanced GIST patients who’ve progressed on imatinib access to #bezuclastinib + #sunitinib. For more information: bit.ly/CB-EAP
#EAP #GISTEducation #ExpandedAccessProgram #clinicaltrials